Economic evaluation alongside the PAOLA-1 /ENGOT-ov25 trial: cost of ovarian cancer and cost-effectiveness of olaparib plus bevacizumab first-line maintenance
- DOI
- 10.1186/s12962-026-00810-4
- Published
- 2026-08-06
- Container
- Cost Effectiveness and Resource Allocation
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1186/s12962-026-00810-4,
title = {Economic evaluation alongside the PAOLA-1 /ENGOT-ov25 trial: cost of ovarian cancer and cost-effectiveness of olaparib plus bevacizumab first-line maintenance},
author = {Lionel Perrier and Kevin Zarca and Thomas Cadet and Magali Morelle and Claire Cropet and Alexandre Burges and Sabrina Chiara Cecere and Isabel Palacio and Cyril Abdeddaim and Isabelle Durand-Zaleski and Isabelle Ray-Coquard},
year = {2026},
journal = {Cost Effectiveness and Resource Allocation},
doi = {10.1186/s12962-026-00810-4},
url = {https://doi.org/10.1186/s12962-026-00810-4}
}RIS
TY - JOUR TI - Economic evaluation alongside the PAOLA-1 /ENGOT-ov25 trial: cost of ovarian cancer and cost-effectiveness of olaparib plus bevacizumab first-line maintenance AU - Lionel Perrier AU - Kevin Zarca AU - Thomas Cadet AU - Magali Morelle AU - Claire Cropet AU - Alexandre Burges AU - Sabrina Chiara Cecere AU - Isabel Palacio AU - Cyril Abdeddaim AU - Isabelle Durand-Zaleski AU - Isabelle Ray-Coquard PY - 2026 JO - Cost Effectiveness and Resource Allocation DO - 10.1186/s12962-026-00810-4 UR - https://doi.org/10.1186/s12962-026-00810-4 ER -
APA
Perrier, L., Zarca, K., Cadet, T., Morelle, M., Cropet, C., Burges, A., Cecere, S. C., Palacio, I., Abdeddaim, C., Durand-Zaleski, I., & Ray-Coquard, I. (2026). Economic evaluation alongside the PAOLA-1 /ENGOT-ov25 trial: cost of ovarian cancer and cost-effectiveness of olaparib plus bevacizumab first-line maintenance. Cost Effectiveness and Resource Allocation. https://doi.org/10.1186/s12962-026-00810-4
Source records
- crossref · retrieved 2026-11-06T23:44:58.698Z